![]() |
Volumn 49, Issue 6, 2013, Pages 399-410
|
White paper: An outlook on U.S. biosimilar competition
|
Author keywords
Biologics price competition and innovation act; Biosimilar user fee act; Biosimilars; Patient protection and affordable care act
|
Indexed keywords
ADALIMUMAB;
BEVACIZUMAB;
CANAKINUMAB;
CETUXIMAB;
ECULIZUMAB;
ETANERCEPT;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
NATALIZUMAB;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
PALIVIZUMAB;
RANIBIZUMAB;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
RECOMBINANT PROTEIN;
RITUXIMAB;
TRASTUZUMAB;
USTEKINUMAB;
ARTICLE;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE POLICY;
LANDSCAPE;
LEGAL ASPECT;
PATENT;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRODUCT DEVELOPMENT;
PUBLIC HEALTH SERVICE;
SENSITIVITY AND SPECIFICITY;
UNITED STATES;
WORLD HEALTH ORGANIZATION;
BIOLOGICS PRICE COMPETITION AND INNOVATION ACT;
BIOSIMILAR USER FEE ACT;
BIOSIMILARS;
PATIENT PROTECTION AND AFFORDABLE CARE ACT;
BIOSIMILAR PHARMACEUTICALS;
CLINICAL TRIALS AS TOPIC;
DRUG AND NARCOTIC CONTROL;
DRUG INDUSTRY;
PATENTS AS TOPIC;
TERMINOLOGY AS TOPIC;
UNITED STATES;
|
EID: 84880031596
PISSN: 16993993
EISSN: 16994019
Source Type: Journal
DOI: 10.1358/dot.2013.49.6.2012938 Document Type: Article |
Times cited : (7)
|
References (16)
|